SIOPEN

  • International Society of Paediatric Oncology Europe Neuroblastoma

Immunotherapy

 

The immunotherapy committee is chaired by Dr Holger Lode.

Immunotherapy involves using the immune system to kill cancer cells. A number of different immunotherapy approaches are being studied and developed for treating neuroblastoma. These include the use of an antibody directed against a molecule called GD2 that is expressed on the surface of neuroblastoma cells. The antibody binds to these cells and then triggers the body's own immune cells to attack and kill the neuroblastoma cell. SIOPEN is currently investigating the best way to give the antibody and also studying whether it is beneficial to give cytokines to stimulate the immune system at the same time. Other immunotherapy approaches using immune cells, rather than antibodies, are currently being developed.

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information

SIOPEN

SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.